Xanelim BLA filing
Executive Summary
Genentech and Xoma will conduct an additional pharmacokinetics study to confirm equivalence between Xanelim (efalizumab) material used for clinical testing and commercial lots. The trial will delay the estimated BLA filing date until summer 2002. Genentech had planned to file a BLA in the first quarter of 2002 (1"The Pink Sheet" Aug. 6, p. 20)